Vertex, Inc.(VERX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VERX Vertex, Inc.

Not Yet Opened 12-22 16:00:00 EST

20.26

+0.24

+1.20%

盘后20.52

+0.26+1.28%

19:46 EST

High20.70	Low20.04	Vol1.01M
Open20.08	D1 Closing20.02	Amplitude3.30%
Mkt Cap3.23B	Tradable Cap1.42B	Total Shares159.53M
T/O20.54M	T/O Rate1.44%	Tradable Shares70.11M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VERX","market":"US","secType":"STK","nameCN":"Vertex, Inc.","latestPrice":20.26,"timestamp":1766437200000,"preClose":20.02,"halted":0,"volume":1009107,"hourTrading":{"tag":"盘后","latestPrice":20.52,"preClose":20.26,"latestTime":"19:46 EST","volume":30676,"amount":621580.17,"timestamp":1766450806248},"delay":0,"floatShares":70114192,"shares":159527964,"eps":-0.338926,"marketStatus":"Not Yet Opened","change":0.24,"latestTime":"12-22 16:00:00 EST","open":20.08,"high":20.7,"low":20.04,"amount":20536829.001215998,"amplitude":0.032967,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.338926,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766480400000},"marketStatusCode":0,"adr":0,"listingDate":1595995200000,"exchange":"NASDAQ","adjPreClose":20.02,"preHourTrading":{"tag":"盘前","latestPrice":20.22,"preClose":20.02,"latestTime":"08:46 EST","volume":11,"amount":222.359984,"timestamp":1766411198808},"postHourTrading":{"tag":"盘后","latestPrice":20.52,"preClose":20.26,"latestTime":"19:46 EST","volume":30676,"amount":621580.17,"timestamp":1766450806248},"volumeRatio":0.678343,"impliedVol":0.5228,"impliedVolPercentile":0.6386},"requestUrl":"/m/hq/s/VERX","defaultTab":"news","newsList":[{"id":"2593463513","title":"Vertex Minerals' Gold Production Continues to Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2593463513","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593463513?lang=en_us&edition=fundamental","pubTime":"2025-12-23 11:32","pubTimestamp":1766460725,"startTime":"0","endTime":"0","summary":"Vertex Minerals  said its gold production continues to rise due to increased underground stoping ore and higher grades at the Reward gold mine in New South Wales, according to a Tuesday filing with the Australian bourse.The company will focus on improving the stoping rate to achieve a steady state, anticipated to boost gold grade at the gravity mill, the filing said.Additionally, the company posted quarter-to-date gold sales of AU$656,708, with two further deliveries of gravity concentrate set for refining before the end of the month, per the filing.Shares fell 2% in afternoon trade on Tuesday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BZ9MQY76.HKD","IE00B19Z9Z06.USD","VERX","LU1035775433.USD","LU0061475181.USD","LU1585245621.USD","VRTX","LU2362541513.USD","IE0009355771.USD","IE00B2B36J28.USD","1OZmain","LU0889565916.HKD","LU2462157665.USD","IE00BJJMRZ35.SGD","LU2456880835.USD","BK4023","LU0823416689.USD","BK4585","IE00B4R5TH58.HKD","LU1674673428.USD","BK7104","LU0079474960.USD","LU2324357040.USD","LU0417517546.SGD","LU2236285917.USD","LU0320765992.SGD","LU1093756168.USD","BK4588","LU0566484027.USD","LU0757428866.USD","VTX.AU","LU1778281490.HKD","BK4139","SGXZ57979304.SGD","LU0432979614.USD","IE00BFTCPJ56.SGD","IE00B19Z9P08.USD","LU2417539215.USD","IE0002270589.USD","IE00B19Z3581.USD","LU1674673691.USD","LU1069344957.HKD","SG9999001176.USD","BK4109","IE00B19Z3B42.SGD","BK4532","LU0256863811.USD","SG9999013999.USD","MTX","LU0058720904.USD"],"gpt_icon":0},{"id":"2593861144","title":"Is CASGEVY’s Pediatric Breakthrough And Priority Review Altering The Investment Case For Vertex (VRTX)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2593861144","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593861144?lang=en_us&edition=fundamental","pubTime":"2025-12-21 02:15","pubTimestamp":1766254516,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals recently reported new clinical data showing that all evaluable children aged 5–11 treated with CASGEVY achieved key endpoints in sickle cell disease and transfusion-dependent beta thalassemia, and also secured an FDA National Priority Voucher to accelerate review in this younger age group.\nBy pairing strong pediatric efficacy signals with an expedited U.S. regulatory review pathway, Vertex is strengthening CASGEVY’s potential role in reshaping treatment for severe...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/36235-main-header/1756253398031","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/36235-main-header/1756253398031"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/is-casgevys-pediatric-breakthrough-and-priority-review-alter","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/is-casgevys-pediatric-breakthrough-and-priority-review-alter","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2362540622.SGD","LU0234570918.USD","IE00B19Z9Z06.USD","SGXZ57979304.SGD","LU1069344957.HKD","BK4567","IE00BZ9MQY76.HKD","LU0109394709.USD","LU0432979614.USD","LU2236285917.USD","LU2456880835.USD","LU2362541273.HKD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU0566484027.USD","BK4585","IE00B4R5TH58.HKD","BK4533","IE00B19Z3B42.SGD","BK4139","LU0289739699.SGD","IE00BJT1NW94.SGD","BK4588","IE00B894F039.SGD","BK4023","LU0058720904.USD","LU1093756325.SGD","LU1585245621.USD","LU0256863811.USD","IE0009355771.USD","LU2324357040.USD","LU1035775433.USD","LU1674673691.USD","IE0002141913.USD","IE00B2B36J28.USD","LU2362541513.USD","LU0079474960.USD","BK4532","LU1093756168.USD","LU0889565916.HKD","LU1674673428.USD","LU2462157665.USD","IE00B19Z9P08.USD","VERX","LU0823416689.USD","LU0417517546.SGD","SG9999001176.USD","LU0061475181.USD","VRTX","LU1815336091.USD"],"gpt_icon":0},{"id":"2592909821","title":"Vertex Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2592909821","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592909821?lang=en_us&edition=fundamental","pubTime":"2025-12-20 05:37","pubTimestamp":1766180220,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Vertex Pharmaceuticals Inc.  rallied 1.97% to $456.20 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index  rising 0.88% to 6,834.50 and the Dow Jones Industrial Average  rising 0.38% to 48,134.89.The stock's rise snapped a three-day losing streak.Vertex Pharmaceuticals Inc. closed 12.22% below its 52-week high of $519.68, which the company reached on March 14th.The stock demonstrated a mixed performance when compared to some of its competitors Friday, as AbbVie Inc.  rose 1.80% to $226.82, Krystal Biotech Inc.  rose 3.18% to $240.80, and Arcturus Therapeutics Holdings Inc.  rose 1.56% to $6.53.Trading volume  eclipsed its 50-day average volume of 1.3 M.Data source: Dow Jones Market Data, FactSet. Data compiled December 19, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is p","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRTX","VERX"],"gpt_icon":0},{"id":"2592459519","title":"Vertex Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2592459519","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592459519?lang=en_us&edition=fundamental","pubTime":"2025-12-18 05:38","pubTimestamp":1766007480,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Vertex Pharmaceuticals Inc.  slid 1.20% to $449.52 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index  falling 1.16% to 6,721.43 and Dow Jones Industrial Average  falling 0.47% to 47,885.97.This was the stock's second consecutive day of losses.Vertex Pharmaceuticals Inc. closed 13.50% short of its 52-week high of $519.68, which the company reached on March 14th.The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as AbbVie Inc.  rose 0.29% to $224.31, Krystal Biotech Inc.  fell 1.15% to $235.80, and Arcturus Therapeutics Holdings Inc.  fell 8.56% to $6.52.Data source: Dow Jones Market Data, FactSet. Data compiled December 17, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The W","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VERX","VRTX"],"gpt_icon":0},{"id":"2592911603","title":"Vertex Pharmaceuticals (VRTX): Valuation Check After Positive Pediatric CASGEVY Data and Priority FDA Review Voucher","url":"https://stock-news.laohu8.com/highlight/detail?id=2592911603","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592911603?lang=en_us&edition=fundamental","pubTime":"2025-12-17 21:18","pubTimestamp":1765977510,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals (VRTX) just delivered encouraging pediatric data for its gene editing therapy CASGEVY in sickle cell and beta thalassemia, and secured an FDA priority voucher that could accelerate review for children ages 5 to 11.\nSee our latest analysis for Vertex Pharmaceuticals.\nInvestors seem to be warming back up to that growth story, with Vertex’s share price at around $454.96 and a solid 90 day share price return of 17.52 percent. This is occurring even though the 1 year total...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/36235-main-header/1756253398031","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/36235-main-header/1756253398031"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/vertex-pharmaceuticals-vrtx-valuation-check-after-positive-p","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/vertex-pharmaceuticals-vrtx-valuation-check-after-positive-p","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0889565916.HKD","IE00BZ9MQY76.HKD","SGXZ57979304.SGD","BK4139","IE00B19Z3581.USD","IE00B19Z9P08.USD","LU0256863811.USD","IE00BJT1NW94.SGD","BK4588","IE00B2B36J28.USD","LU0566484027.USD","LU1815336091.USD","LU0289739699.SGD","IE0009355771.USD","IE0002270589.USD","SG9999001176.USD","LU0234570918.USD","BK4023","BK4532","BK4533","LU1035775433.USD","LU0417517546.SGD","IE00B4R5TH58.HKD","LU2417539215.USD","VRTX","VERX","IE00B19Z9Z06.USD","SG9999001176.SGD","LU2456880835.USD","LU2324357040.USD","LU0109394709.USD","SG9999013999.USD","LU1674673428.USD","LU2237438978.USD","IE00BJJMRZ35.SGD","IE0002141913.USD","LU2462157665.USD","LU1778281490.HKD","LU0432979614.USD","IE00B19Z3B42.SGD","LU0079474960.USD","LU1430594728.SGD","LU0320765992.SGD","LU0823416689.USD","LU1559883803.SGD","BK4567","LU2362541513.USD","IE00BFTCPJ56.SGD","BK4585","LU1093756325.SGD"],"gpt_icon":0},{"id":"2590269553","title":"Vertex Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2590269553","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590269553?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:39","pubTimestamp":1765402740,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Vertex Pharmaceuticals Inc.  rallied 1.75% to $444.64 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index  rising 0.67% to 6,886.68 and the Dow Jones Industrial Average  rising 1.05% to 48,057.75.The stock's rise snapped a four-day losing streak.Vertex Pharmaceuticals Inc. closed 14.44% short of its 52-week high of $519.68, which the company achieved on March 14th.The stock demonstrated a mixed performance when compared to some of its competitors Wednesday, as AbbVie Inc.  rose 0.98% to $225.18, Krystal Biotech Inc.  rose 2.17% to $239.72, and Arcturus Therapeutics Holdings Inc.  rose 6.53% to $7.67.Trading volume  remained 414,067 below its 50-day average volume of 1.4 M.Data source: Dow Jones Market Data, FactSet. Data compiled December 10, 2025.This content was created by MarketWatch, which is operated by Dow Jones & ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRTX","VERX"],"gpt_icon":0},{"id":"2590058435","title":"Wells Fargo Adjusts PT on Vertex Pharmaceuticals to $515 From $460, Maintains Overweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2590058435","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590058435?lang=en_us&edition=fundamental","pubTime":"2025-12-10 20:11","pubTimestamp":1765368673,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals (VRTX) has an average rating of overweight and mean price target of $494.44, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PT","VRTX","VERX"],"gpt_icon":0},{"id":"2590307522","title":"Vertex 1H Net Y1.44B Vs Net Y1.45B","url":"https://stock-news.laohu8.com/highlight/detail?id=2590307522","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590307522?lang=en_us&edition=fundamental","pubTime":"2025-12-10 16:43","pubTimestamp":1765356180,"startTime":"0","endTime":"0","summary":"This content was automatically published based on data and/or text from the original source. For feedback, write to singaporeeditors@dowjones.com.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0061475181.USD","IE00B19Z3B42.SGD","BK4023","LU1815336091.USD","BK4533","LU0109394709.USD","LU2324357040.USD","IE0002141913.USD","BK4567","LU1674673691.USD","VRTX","IE00B894F039.SGD","LU0823416689.USD","LU0432979614.USD","IE00BJJMRZ35.SGD","LU0889565916.HKD","IE0009355771.USD","BK4139","IE00BFTCPJ56.SGD","LU0320765992.SGD","BK4532","LU0289739699.SGD","LU2236285917.USD","SG9999001176.SGD","LU0566484027.USD","LU0256863811.USD","LU1093756325.SGD","LU1674673428.USD","LU2462157665.USD","LU1778281490.HKD","SG9999001176.USD","LU1430594728.SGD","SGXZ57979304.SGD","LU0757428866.USD","IE00B19Z9P08.USD","LU1093756168.USD","LU1585245621.USD","LU2456880835.USD","LU0079474960.USD","LU1559883803.SGD","LU2362540622.SGD","LU2237438978.USD","IE0002270589.USD","LU2362541513.USD","IE00B19Z9Z06.USD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","VERX","IE00B19Z3581.USD","IE00BZ9MQY76.HKD"],"gpt_icon":0},{"id":"2590932366","title":"Vertex Pharmaceuticals Inc. Stock Underperforms Monday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2590932366","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590932366?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:38","pubTimestamp":1765229880,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Vertex Pharmaceuticals Inc.  slid 2.95% to $442.04 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index  falling 0.35% to 6,846.51 and Dow Jones Industrial Average  falling 0.45% to 47,739.32.This was the stock's third consecutive day of losses.Vertex Pharmaceuticals Inc. closed 14.94% below its 52-week high of $519.68, which the company reached on March 14th.The stock underperformed when compared to some of its competitors Monday, as AbbVie Inc.  fell 1.31% to $223.12, Krystal Biotech Inc.  fell 0.03% to $234.05, and Arcturus Therapeutics Holdings Inc.  rose 4.49% to $7.45.Trading volume  eclipsed its 50-day average volume of 1.4 M.Data source: Dow Jones Market Data, FactSet. Data compiled December 8, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently fro","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRTX","VERX"],"gpt_icon":0},{"id":"2589554843","title":"Vertex's Gene Therapy Works In Children With Blood Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2589554843","media":"Benzinga","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589554843?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:18","pubTimestamp":1765199880,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals Incorporated  on Saturday presented data from multiple studies demonstrating the clinical benefits of Casgevy  in patients aged 5 years and older with severe sickle cell disease  or transfusion-dependent beta thalassemia .SCD is a severe inherited blood disease that damages red blood cells, limits oxygen delivery, causes intense pain, and can shorten life.TDT is a life-threatening genetic condition that forces patients to rely on regular blood transfusions and lifelong treatment to remove excess iron.Also Read: FDA Fast-Tracks 6 More Drugs – Obesity And Cancer Drugs Included. In children with SCD, 11 patients have been dosed with Casgevy in the Phase 3 CLIMB-151 clinical study, and all (4/4) patients with sufficient follow-up achieved the primary endpoint of being free from vaso-occlusive crises  for at least 12 consecutive months .In children with TDT, 13 patients have been dosed with Casgevy in the Phase 3 CLIMB-141 clinical study, and all (6/6) patients with s","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/08/Vertex-Pharmaceuticals-Inc-.jpeg?optimize=medium&dpr=2&auto=webp&width=630","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/08/Vertex-Pharmaceuticals-Inc-.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/25/12/49254689/vertexs-gene-therapy-works-in-children-with-blood-disorders","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/12/49254689/vertexs-gene-therapy-works-in-children-with-blood-disorders","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["IE00B19Z3B42.SGD","LU2362541513.USD","IE00B2B36J28.USD","LU2462157665.USD","LU2237438978.USD","IE00B19Z9P08.USD","LU2463526074.USD","BK4139","LU1778281490.HKD","LU0109394709.USD","LU2417539215.USD","LU0417517546.SGD","LU0432979614.USD","BK4532","LU1585245621.USD","BK4567","IE00B19Z9Z06.USD","IE00BJJMRZ35.SGD","BK4588","LU1674673428.USD","SG9999001176.USD","SG9999013999.USD","LU1093756168.USD","LU1093756325.SGD","VRTX","IE00BZ9MQY76.HKD","LU1069344957.HKD","IE00BFTCPJ56.SGD","LU0058720904.USD","LU1815336091.USD","IE0002270589.USD","IE00BJT1NW94.SGD","IE0002141913.USD","LU0289739699.SGD","LU0320765992.SGD","VERX","IE00B19Z3581.USD","ASH","LU0234570918.USD","LU0889565916.HKD","LU0256863811.USD","IE00B894F039.SGD","LU1674673691.USD","LU0823416689.USD","LU0061475181.USD","SG9999001176.SGD","LU2324357040.USD","LU0566484027.USD","SCD","IE0009355771.USD"],"gpt_icon":0},{"id":"2589476382","title":"Reassessing Vertex Pharmaceuticals After Pipeline Progress and Recent 7% Share Price Jump","url":"https://stock-news.laohu8.com/highlight/detail?id=2589476382","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589476382?lang=en_us&edition=fundamental","pubTime":"2025-12-08 13:16","pubTimestamp":1765171012,"startTime":"0","endTime":"0","summary":"If you are wondering whether Vertex Pharmaceuticals at around $455 a share is still a smart buy or if the best days are already priced in, you are not alone.\nThe stock has climbed 7.0% over the last week and 11.2% over the past month. It is still only up 12.3% year to date and is actually down 3.9% over the last year, despite a strong 45.0% three year and 99.7% five year run.\nRecent headlines have focused on Vertex's expanding pipeline in cystic fibrosis and non opioid pain, along with...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/36235-main-header/1756253398031","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/36235-main-header/1756253398031"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/reassessing-vertex-pharmaceuticals-after-pipeline-progress-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/reassessing-vertex-pharmaceuticals-after-pipeline-progress-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0058720904.USD","LU0061475181.USD","LU0889565916.HKD","IE00BZ9MQY76.HKD","SGXZ57979304.SGD","BK4139","IE00B19Z3581.USD","IE00B19Z9P08.USD","LU1069344957.HKD","LU0566484027.USD","BK4588","IE00B2B36J28.USD","LU1815336091.USD","LU0289739699.SGD","IE0009355771.USD","SG9999001176.USD","LU0234570918.USD","LU2065732104.USD","BK4023","LU0757428866.USD","BK4532","BK4533","LU1035775433.USD","LU1585245621.USD","IE00B4R5TH58.HKD","LU1093756168.USD","VRTX","VERX","LU2362540622.SGD","IE00B19Z9Z06.USD","SG9999001176.SGD","LU2456880835.USD","LU0109394709.USD","PRGS","DCF","IE00BJJMRZ35.SGD","LU1674673691.USD","IE0002141913.USD","LU2462157665.USD","LU1778281490.HKD","LU0432979614.USD","IE00B19Z3B42.SGD","LU1430594728.SGD","LU0320765992.SGD","BK4567","LU1093756325.SGD","LU2362541513.USD","IE00BFTCPJ56.SGD","LU2236285917.USD","IE00B894F039.SGD"],"gpt_icon":0},{"id":"2589038863","title":"Vertex Minerals Says New South Wales Gold Mine Underground Loader Loads Ore from Stope by Remote Control","url":"https://stock-news.laohu8.com/highlight/detail?id=2589038863","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589038863?lang=en_us&edition=fundamental","pubTime":"2025-12-08 10:44","pubTimestamp":1765161852,"startTime":"0","endTime":"0","summary":"Vertex Minerals  said that the Aramine underground loader loaded ore from the 1438 north stope by remote control at its Reward gold mine in New South Wales, according to a Monday Australian bourse filing.The firm's Chairman, Roger Jackson, said the equipment needed to be purposely commissioned, and the tele remote hut is designed specifically for the Reward mine and can be moved around on a skid steer.Its gold production ramp-up is progressing, and the firm is beginning to see gold grades increase as it goes to areas of planned development and production activity.The firm's shares fell 2% in recent trading on Monday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","LU2456880835.USD","BK4533","SG9999001176.SGD","LU1430594728.SGD","VERX","IE00B19Z3581.USD","LU0256863811.USD","BK4588","SG9999013999.USD","LU0061475181.USD","MTX","LU2417539215.USD","IE0002270589.USD","LU0109394709.USD","LU1585245621.USD","IE00B19Z9P08.USD","LU2362540622.SGD","LU2362541513.USD","LU0889565916.HKD","LU2462157665.USD","BK4532","LU1674673691.USD","LU0234570918.USD","LU1093756325.SGD","IE00BFTCPJ56.SGD","IE00B894F039.SGD","LU0058720904.USD","IE00BZ9MQY76.HKD","SG9999001176.USD","LU2237438978.USD","LU1674673428.USD","IE00B4R5TH58.HKD","VRTX","BK4109","LU0320765992.SGD","BK4023","LU0417517546.SGD","LU1035775433.USD","VTX.AU","BK7104","BK4567","1OZmain","LU0079474960.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU1559883803.SGD","LU0566484027.USD","LU0823416689.USD","LU0757428866.USD"],"gpt_icon":0},{"id":"2589787457","title":"Vertex (VERX): Valuation Check After Expanded AI Tax Compliance Partnership With CPA.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2589787457","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589787457?lang=en_us&edition=fundamental","pubTime":"2025-12-07 18:14","pubTimestamp":1765102474,"startTime":"0","endTime":"0","summary":"Vertex (VERX) has expanded its long-running partnership with CPA.com, rolling out an AI-powered sales tax compliance platform built with Kintsugi. The move directly targets accounting firms looking to automate complex, recurring tax workflows.\nSee our latest analysis for Vertex.\nDespite solid revenue growth and the new AI collaboration with CPA.com and Kintsugi, Vertex’s 90 day share price return of minus 24.1 percent and 1 year total shareholder return of minus 65.05 percent suggest...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/software/nasdaq-verx/vertex/news/vertex-verx-valuation-check-after-expanded-ai-tax-compliance","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/software/nasdaq-verx/vertex/news/vertex-verx-valuation-check-after-expanded-ai-tax-compliance","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0320765992.SGD","LU2462157665.USD","BK4543","LU2362541513.USD","IE0009355771.USD","LU0109394709.USD","LU1093756168.USD","LU0289739699.SGD","BK4139","IE00B4R5TH58.HKD","LU1430594728.SGD","LU1674673428.USD","LU1815336091.USD","SGXZ57979304.SGD","BK4551","LU0889565916.HKD","LU1069344957.HKD","BK4588","LU0566484027.USD","SG9999001176.USD","BK4023","LU1674673691.USD","LU2362541273.HKD","LU2417539215.USD","BK4533","LU0432979614.USD","IE0002270589.USD","BK4532","LU1093756325.SGD","VERX","IE00BFTCPJ56.SGD","IE00BZ9MQY76.HKD","LU0757428866.USD","IE00B19Z3B42.SGD","LU1778281490.HKD","LU2236285917.USD","LU2324357040.USD","IE00B894F039.SGD","LU0061475181.USD","BK4528","IE00B19Z9Z06.USD","AI","LU0823416689.USD","IE0002141913.USD","IE00B19Z9P08.USD","LU2237438978.USD","IE00B19Z3581.USD","LU0058720904.USD","VRTX","LU1559883803.SGD"],"gpt_icon":0},{"id":"2589849595","title":"Vertex (VRTX) Kidney Pipeline Upgrades: A Turning Point in Its Diversification Strategy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2589849595","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589849595?lang=en_us&edition=fundamental","pubTime":"2025-12-06 09:40","pubTimestamp":1764985257,"startTime":"0","endTime":"0","summary":"Recently, Morgan Stanley and other analysts upgraded their views on Vertex Pharmaceuticals, citing growing confidence in its kidney disease pipeline, particularly povetacicept and inaxaplin, which are progressing through late-stage clinical trials.\nThis renewed focus on Vertex’s kidney candidates highlights how successfully broadening beyond cystic fibrosis treatments could reshape the company’s long-term revenue mix and risk profile.\nWe’ll now explore how this increased optimism around...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/36235-main-header/1756253398031","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/36235-main-header/1756253398031"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/vertex-vrtx-kidney-pipeline-upgrades-a-turning-point-in-its","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vrtx/vertex-pharmaceuticals/news/vertex-vrtx-kidney-pipeline-upgrades-a-turning-point-in-its","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TPB","VRTX","VERX"],"gpt_icon":0},{"id":"2589244897","title":"Morgan Stanley Adjusts PT on Vertex Pharmaceuticals to $564 From $516, Maintains Overweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2589244897","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589244897?lang=en_us&edition=fundamental","pubTime":"2025-12-05 21:16","pubTimestamp":1764940568,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals (VRTX) has an average rating of overweight and mean price target of $492.24, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PT","VERX","VRTX"],"gpt_icon":0},{"id":"2589698897","title":"Vertex and CPA.com Launch AI-Driven Sales Tax Compliance Solution for Accounting Firms","url":"https://stock-news.laohu8.com/highlight/detail?id=2589698897","media":"Reuters","labels":["corporation","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589698897?lang=en_us&edition=fundamental","pubTime":"2025-12-05 21:00","pubTimestamp":1764939624,"startTime":"0","endTime":"0","summary":"Vertex Inc. has expanded its partnership with CPA.com to launch an AI-driven solution for sales tax compliance, in collaboration with Kintsugi. This initiative aims to help accounting firms of all sizes automate and streamline sales tax compliance, from exposure analysis and registration to filing and reporting. The enhanced offering, available through CPA.com's Firm Advisor Program, allows firms to either manage compliance directly via a white-labelled platform or refer clients for fully automated support. The solution integrates with leading ERP, billing, and e-commerce systems, providing dedicated support, fast setup, and transparent workflows to help accounting teams scale their services and unlock new revenue opportunities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL8yfmKy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00B3QW5Z07.USD","LU1559883803.SGD","LU1815336091.USD","LU2095319765.USD","LU0566484027.USD","IE00BGHQF748.EUR","VERX","LU0314104364.USD","LU0757428866.USD","BK4585","IE00B64PRP62.GBP","NDAQ","BK4588","LU2210149790.SGD","LU2210150020.SGD","BK4023","BK4112"],"gpt_icon":0},{"id":"2589183618","title":"Sionna Therapeutics Valuation Topping $2 Billion Is 'Too Optimistic', RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2589183618","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589183618?lang=en_us&edition=fundamental","pubTime":"2025-12-05 00:45","pubTimestamp":1764866728,"startTime":"0","endTime":"0","summary":"Sionna Therapeutics'  valuation topping $2 billion is \"too optimistic\" as the company's early-stage cystic fibrosis program faces significant hurdles before proving itself in clinical trials, RBC Capital Markets said Thursday in a report.Interest in Sionna has been fueled by hopes of major upside and the stock's perceived connection to widely held Vertex Pharmaceuticals , and investor feedback to RBC's downgrade of Sionna on Monday to underperform from sector perform triggered \"significant feedback,\" according to the report.Sionna is developing small-molecule drugs designed to work alongside Vertex's widely used therapy Trikafta, aiming to improve outcomes for cystic fibrosis patients, the report said.RBC cited variability in Sionna's human bronchial epithelial assays, where Trikafta's performance appeared weaker than in Vertex's published studies, raising questions about the reliability of Sionna's comparisons and the likelihood of clinical benefit.Despite investor pushback, RBC maint","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B19Z9P08.USD","SGXZ57979304.SGD","LU0320765992.SGD","BK4533","LU0889565916.HKD","LU1778281490.HKD","IE00B19Z9Z06.USD","BK4023","LU1069344957.HKD","LU2417539215.USD","LU2362541513.USD","VERX","LU1093756168.USD","BK4567","IE00B894F039.SGD","LU0256863811.USD","BK4532","LU1430594728.SGD","IE00B19Z3B42.SGD","LU0234570918.USD","IE0002141913.USD","IE0009355771.USD","LU1815336091.USD","LU2236285917.USD","BK4139","IE00B19Z3581.USD","SG9999001176.SGD","IE00BJT1NW94.SGD","LU2362541273.HKD","VRTX","LU2324357040.USD","SG9999001176.USD","SG9999013999.USD","IE00BFTCPJ56.SGD","BK4585","IE00BJJMRZ35.SGD","LU2462157665.USD","LU1585245621.USD","LU0823416689.USD","LU1674673691.USD","IE0002270589.USD","LU0289739699.SGD","LU2456880835.USD","LU0417517546.SGD","LU2362540622.SGD","IE00B4R5TH58.HKD","LU0757428866.USD","LU0109394709.USD","LU1093756325.SGD","SION"],"gpt_icon":0},{"id":"2588235620","title":"Vertex Pharmaceuticals Up Over 5%, on Pace for Largest Percent Increase Since November 2024 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2588235620","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588235620?lang=en_us&edition=fundamental","pubTime":"2025-12-04 01:03","pubTimestamp":1764781380,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals Incorporated  is currently at $457.50, up $24.36 or 5.62%. --Would be highest close since Aug. 4, 2025, when it closed at $472.27. --On pace for largest percent increase since Nov. 5, 2024, when it rose 5.73%. --Currently up two consecutive days; up 7.5% over this period. --Up 13.61% year-to-date; on pace for best year since 2023, when it rose 40.9%. --Down 11.46% from its all-time closing high of $516.74 on Nov. 8, 2024. --Down 1.40% from 52 weeks ago , when it closed at $463.98. --Up 24.82% from its 52-week closing low of $366.54 on Aug. 8, 2025. --Traded as high as $461.38; highest intraday level since Aug. 4, 2025, when it hit $473.37. --Up 6.52% at today's intraday high; largest intraday percent increase since Jan. 31, 2025, when it rose as much as 7.67%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU1674673428.USD","IE00B2B36J28.USD","BK4533","BK4532","LU1778281490.HKD","IE00BZ9MQY76.HKD","BK4567","LU2362540622.SGD","BK4585","LU1674673691.USD","LU0566484027.USD","LU1559883803.SGD","IE00B19Z3581.USD","LU0432979614.USD","LU0256863811.USD","LU0823416689.USD","IE00B4R5TH58.HKD","LU1069344957.HKD","LU1430594728.SGD","SG9999013999.USD","LU0289739699.SGD","LU2456880835.USD","LU0058720904.USD","LU0417517546.SGD","IE0002270589.USD","LU0757428866.USD","LU1093756168.USD","LU2324357040.USD","IE00BJJMRZ35.SGD","VERX","LU2417539215.USD","SGXZ57979304.SGD","LU0889565916.HKD","LU1093756325.SGD","VRTX","LU0079474960.USD","LU2462157665.USD","LU0109394709.USD","IE00B894F039.SGD","IE00B19Z3B42.SGD","LU0061475181.USD","IE0009355771.USD","IE00B19Z9P08.USD","LU2237438978.USD","BK4588","LU1035775433.USD","LU2362541513.USD","SG9999001176.SGD","SG9999001176.USD"],"gpt_icon":0},{"id":"2588868028","title":"Vertex Pharmaceuticals' Kidney Pipeline Seen as Growth Driver, Morgan Stanley Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2588868028","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588868028?lang=en_us&edition=fundamental","pubTime":"2025-12-04 00:05","pubTimestamp":1764777916,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals' (VRTX) kidney drug candidates Pove and Inaxaplin to significantly boost long-term revenue and profit growth if successful in upcoming phase 3 trials, Morgan Stanley said in a n","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1244550577.SGD","IE0009355771.USD","LU1363072403.SGD","BK4588","LU1720051017.SGD","LU2417539215.USD","IE00BFTCPJ56.SGD","LU2028103732.USD","IE00BZ1G4Q59.USD","LU0320765992.SGD","LU2271345857.HKD","LU1720051108.HKD","BK4023","LU2236285917.USD","LU1732799900.SGD","LU0158827948.USD","LU1791710582.SGD","VERX","LU0557290698.USD","LU2362541273.HKD","SG9999013999.USD","BK4127","LU2357305700.SGD","LU1035775433.USD","LU2089283258.USD","LU0061475181.USD","LU2133065610.SGD","VRTX","LU0289739699.SGD","IE00B19Z9Z06.USD","LU0320765646.SGD","LU0528227936.USD","LU2456880835.USD","BK4567","BK4581","LU1585245621.USD","BK4533","LU2362540622.SGD","LU0058720904.USD","LU0566484027.USD","LU1674673691.USD","LU1244550221.USD","LU0314104364.USD","LU1989772840.SGD","LU2462157665.USD","LU2324357040.USD","BK4516","LU0417517546.SGD","LU1244550494.USD","LU0971096721.USD"],"gpt_icon":0},{"id":"2588404390","title":"Vertex Pharmaceuticals Raised to Overweight From Equal-Weight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2588404390","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588404390?lang=en_us&edition=fundamental","pubTime":"2025-12-03 23:45","pubTimestamp":1764776700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VRTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 03, 2025 10:45 ET (15:45 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VERX","VRTX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vertexinc.com","stockEarnings":[{"period":"1week","weight":0.0411},{"period":"1month","weight":0.0237},{"period":"3month","weight":-0.197},{"period":"6month","weight":-0.3943},{"period":"1year","weight":-0.6215},{"period":"ytd","weight":-0.6202}],"compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":0.0391},{"period":"3month","weight":0.0326},{"period":"6month","weight":0.128},{"period":"1year","weight":0.1585},{"period":"ytd","weight":0.1685}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vertex, Inc. provides tax technology solutions for retail, communication, leasing, retail trade, wholesale trade, technology, and manufacturing industries in the United States and internationally. It offers tax determination, compliance and reporting, tax data management, document management, analytics and insights, pre-built integration, and industry-specific solutions. The company sells its software products through software license and software as a service subscriptions. It also provides implementation and training services in connection with its software license and cloud subscriptions, transaction tax returns outsourcing, and other tax-related services. Vertex, Inc. was founded in 1978 and is headquartered in King of Prussia, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.04594},{"month":2,"riseRate":0.4,"avgChangeRate":-0.001304},{"month":3,"riseRate":0.6,"avgChangeRate":0.034808},{"month":4,"riseRate":0.2,"avgChangeRate":-0.016847},{"month":5,"riseRate":0.4,"avgChangeRate":-0.019},{"month":6,"riseRate":0.6,"avgChangeRate":0.007488},{"month":7,"riseRate":0.4,"avgChangeRate":-0.008483},{"month":8,"riseRate":0.666667,"avgChangeRate":0.038495},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.031162},{"month":10,"riseRate":0.833333,"avgChangeRate":0.084182},{"month":11,"riseRate":0.5,"avgChangeRate":0.032922},{"month":12,"riseRate":0.333333,"avgChangeRate":0.011164}],"exchange":"NASDAQ","name":"Vertex, Inc.","nameEN":"Vertex, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vertex, Inc.(VERX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vertex, Inc.(VERX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vertex, Inc.,VERX,Vertex, Inc.股票,Vertex, Inc.股票老虎,Vertex, Inc.股票老虎国际,Vertex, Inc.行情,Vertex, Inc.股票行情,Vertex, Inc.股价,Vertex, Inc.股市,Vertex, Inc.股票价格,Vertex, Inc.股票交易,Vertex, Inc.股票购买,Vertex, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vertex, Inc.(VERX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vertex, Inc.(VERX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction